{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-016370","form_type":"8-K","ticker":"TCMD","cik":"0001027838","company_name":"TACTILE SYSTEMS TECHNOLOGY INC","filed_at":"2026-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.424055+00:00","generated_at":"2026-05-16T02:18:01.930726+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tactile Medical Q4 revenue up 21% to $103.6M; acquires LymphaTech for $6.8M","bullets":["Q4 2025 revenue $103.6M (+21% YoY); net income $10.6M ($0.46 diluted EPS) vs $9.7M ($0.40) in Q4 2024.","Full year 2025 revenue $329.5M (+12% YoY); adjusted EBITDA $44.8M ($37.1M in 2024).","FY2026 guidance: revenue $357-365M (8-11% growth), adjusted EBITDA $49-51M.","Acquired LymphaTech for $6.8M upfront cash plus contingent milestones; adds 3D scanning for lymphedema.","Repaid $26.3M term loan; repurchased $26.5M stock at avg $12.36 per share."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-016370","json":"https://secwatch.observer/filing/0001104659-26-016370.json","markdown":"https://secwatch.observer/filing/0001104659-26-016370.md","text":"https://secwatch.observer/filing/0001104659-26-016370.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1027838/000110465926016370/0001104659-26-016370-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1027838/000110465926016370/tcmd-20260217x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:18:01.930726+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}